However, different from these molecules, which are genetically lost in cancer, PRKN epigenetic silencing in tumors (52, 53) is reversible by clinically approved demethylating therapy (70), which restores endogenous PRKN levels in the tumor microenvironment and associated IFN signaling. This evidence concerns the gene PRKN and neoplasm.